Drug interactions with the taxanes: Clinical implications

Cancer Treatment Reviews

Volumn 27, Issue 4, 2001, Pages 221-233

  Baker, A F ^a   Dorr, R T ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

Combinations; Docetaxel; Drug interactions; Paclitaxel; Taxanes

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; AMIFOSTINE; ANTHRACYCLINE; ANTICONVULSIVE AGENT; ANTINEOPLASTIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOCHROME P450; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLAVOPIRIDOL; FLUOROURACIL; IBANDRONIC ACID; IFOSFAMIDE; IRINOTECAN; PACLITAXEL; PHENOBARBITAL; PHENYTOIN; PROGESTERONE; QUININE; TAXANE DERIVATIVE; TOPOTECAN; UNINDEXED DRUG; VERAPAMIL; VINBLASTINE;

ANTICONVULSANT THERAPY; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CLINICAL RESEARCH; CONTROLLED STUDY; DATA ANALYSIS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG OXIDATION; ENZYME INDUCTION; ENZYME INHIBITION; HUMAN; LIVER METABOLISM; MEDICAL INFORMATION; MEDICAL LITERATURE; PHARMACODYNAMICS; PHARMACOLOGICAL PARAMETERS; SIDE EFFECT; STEADY STATE;

EID: 0034831424     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1053/ctrv.2001.0228     Document Type: Article

References (80)

1. Drug interactions with the taxanes
2. Pharmacology of the taxanes
3. The taxoids. Comparative clinical pharmacology and therapeutic potential
4. Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway
5. Taxanes: An overview of the pharmacokinetics and pharmacodynamics
6. Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8
7. Metabolism of docetaxel by human cytochromes P450: Interactions with paclitaxel and other antineoplastic drugs
8. Role of human cytochrome P450 3A4 and 3A5 in the metabolism of taxotere and its derivatives: Enzyme specificity, interindividual distribution and metabolic contribution in human liver
9. Pharmacokinetics of the taxanes
10. Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL
11. Inhibition of paclitaxel elimination in the isolated perfused rat liver by Cremophor EL
12. Metabolism of taxol by human and rat liver in vitro: A screen for drug interactions and interspecies differences
13. Sequences of taxol and cisplatin: A phase I and pharmacologic study
14. Platinum anticancer drugs modulate P-450 mRNA levels and differentially alter hepatic drug and steroid hormone metabolism in male and female rats
15. Damage of the kinesin heavy chain gene contributes to the antagonism of cisplatin and paclitaxel
16. Cloning mammalian genes by expression selection of genetic suppressor elements: Association of kinesin with drug resistance cell immortalization
17. Phase I and pharmacologic study of docetaxel and cisplatin in patients with advanced solid tumors
18. Compilation of phase I and II trial data of docetaxel and doxorubicin in the treatment of advanced breast cancer and other malignancies
19. Use of dexrazoxane and other strategies to prevent cardiomyopathy associated with doxorubicin-taxane combinations
20. Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paciltaxel and doxorubicin in patients with metastatic breast cancer
21. Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer
22. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study
23. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion
24. Pharmacokinetics of taxol and doxorubicin administered alone and in combination by continuous 72-hour infusion
25. Phase I/II study of 72-hour infusional paclitaxel and doxorubicin with granulocyte colony-stimulating factor in patients with metastatic breast cancer
26. Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer
27. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer
28. Phase I trial of escalating doses of paclitaxel plus doxorubicin and dexrazoxane in patients with advanced breast cancer
29. Comparative effects of paclitaxel and docetaxel on the metabolism and pharmacokinetics of epirubicin in breast cancer patients
30. Sequence effect of epirubicin and paclitaxel treatment on pharmacokinetics and toxicity
31. Preirradiation paclitaxel in glioblastoma multiforme: Efficacy, pharmacology, and drug interactions. New Approaches to Brain Tumor Therapy Central Nervous System Consortium
32. Phase I study of paclitaxel in patients with recurrent malignant glioma: A North American Brain Tumor Consortium report
33. Adverse effect of anticonvulsants on efficacy of chemotherapy for acute lymphoblastic leukaemia
34. Clinical pharmacology of carboplatin administered in combination with paclitaxel
35. Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancer
36. Carboplatin and paclitaxel in ovarian carcinoma: A phase I study of the Gynecologic Oncology Group
37. Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. The European Cancer Centre
38. Evaluation of carboplatin pharmacokinetics in the absence and presence of paclitaxel
39. Pharmacokinetics of paclitaxel and carboplatin in combination
40. Carboplatin in combination with paclitaxel in advanced ovarian cancer: Dose determination and pharmacokinetic and pharmacodynamic interactions
41. Investigating the platelet sparing mechanism of paclitaxel/carboplatin chemotherapy
42. Evidence for a schedule-dependent deleterious interaction between paclitaxel, vinblastine and cisplatin (PVC) in the treatment of advanced transitional cell carcinoma
43. Synergism of cytotoxic effects of vinorelbine and paclitaxel in vitro
44. Amifostine protects normal tissues from paclitaxel toxicity while cytotoxicity against tumour cells is maintained
45. A phase I study of amifostine and paclitaxel in patients with advanced malignancies
46. Influence of the cytoprotective agent amifostine (AMI) on pharmacokinetics (PK) of paclitaxel (PAC) and Taxotere (TXT)
47. Randomized phase II study of high-dose paclitaxel with or without amifostine in patients with metastatic breast cancer
48. Phase I and pharmacologic study of sequences of paclitaxel and cyclophosphamide supported by granulocyte colony-stimulating factor in women with previously treated metastatic breast cancer
49. Phase I study of paclitaxel in combination with cyclophosphamide and granulocyte colony-stimulating factor in metastatic breast cancer patients
50. Pharmacokinetics of ifosfamide are changed by combination with docetaxel: Results of a phase I pharmacologic study
51. In vitro evaluation of schedule-dependent interactions between docetaxel and doxorubicin against human breast and ovarian cancer cells
52. Taxoids in combination with anthracyclines and other agents: Pharmacokinetic considerations
53. A phase II/pharmacokinetic trial of high-dose progesterone in combination with paclitaxel
54. A phase I/II trial of paclitaxel for non-Hodgkin's lymphoma followed by paclitaxel plus quinine in drug-resistant disease
55. A phase I study of pacltaxel (T) with R-verapamil (RV) in metastatic breast cancer (MBC)
56. Effect of R-verapamil on the pharmacokinetics of paclitaxel in women with breast cancer
57. Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: A Gynecologic Oncology Group study
58. Treatment-related fatal sepsis from topotecan/cisplatin and topotecan/paclitaxel
59. Glutathione depletion by L-buthionine sulfoximine antagonizes taxol cytotoxicity
60. Taxol in combination with doxorubicin or etoposide. Possible antagonism in vitro
61. In vitro evaluation of synergism or antagonism with combinations of new cytotoxic agents
62. Sequence-dependent cytotoxicity of etoposide and paclitaxel in human breast and lung cancer cell lines
63. Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: The importance of sequence of administration
64. In vitro schedule-dependent interaction between paclitaxel and SN-38 (the active metabolite of irinotecan) in human carcinoma cell lines
65. Sequence-dependent antagonism between fluorouracil and paclitaxel in human breast cancer cells
66. Schedule-dependent interaction between paclitaxel and 5-fluorouracil in human carcinoma cell lines in vitro
67. A phase I study of docetaxel and 5-fluorouracil in patients with advanced solid malignancies
68. Phase II trial of the combination of paclitaxel and 5-fluorouracil in the treatment of advanced gastric cancer: A novel, safe, and effective regimen
69. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts
70. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers
71. Use of slow Ca2+ channel blockers to enhance inhibition by taxol of growth of drug-sensitive and -resistant Chinese hamster ovary cells
72. Additive antitumor activities of taxoids in combination with the bisphosphonate ibandronate against invasion and adhesion of human breast carcinoma cells to bone
73. Combination chemotherapy using paclitaxel, carboplatin, and bleomycin in human lung cancer cells
74. Rorer Rhone-Poulene Taxotere (docetaxel) package insert
75. Dexamethasone induction of taxol metabolism in the rat
76. In vivo and in vitro induction of human cytochrome P4503A4 by dexamethasone
77. Predicting drug interactions in vivo from experiments in vitro. Human studies with paclitaxel and ketoconazole
78. The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo
79. St John's Wort: Effect on CYP3A4 activity